Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.49 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4772524 | 0.96 | LOXL2 (0.50) | ASIC3RECQLLOXL2PDCD1CD274 | |
| SCHEMBL27822958 | 0.85 | ASIC3 (0.50) | ASIC3LOXL2PDCD1CD274NOTUM | |
| SCHEMBL1411265 | 0.83 | RECQL (0.61) | RECQLLOXL2PDCD1CD274PRKCI | |
| SCHEMBL29393772 | 0.83 | RECQL (0.61) | RECQLLOXL2PDCD1CD274PRKCI | |
| SCHEMBL27822961 | 0.82 | ASIC3 (0.47) | ASIC3LOXL2PDCD1CD274FFAR1 | |
| SCHEMBL11776617 | 0.82 | PDCD1 (0.62) | ASIC3RECQLLOXL2PDCD1CD274 | |
| SCHEMBL4772393 | 0.81 | RECQL (0.56) | RECQLLOXL2NOTUMLMNAMAPT | |
| SCHEMBL14310545 | 0.81 | LOXL2 (0.50) | ASIC3RECQLLOXL2PRKCIKDM1A | |
| SCHEMBL4492835 | 0.81 | RECQL (0.47) | RECQLLOXL2FYNHTR1ANPC1 | |
| SCHEMBL4764104 | 0.81 | RECQL (0.47) | RECQLLOXL2PDCD1CD274KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118165038-A | Cyclic metal ruthenium nitrosyl complex, preparation method and application as NO release photosensitizer | 中南民族大学 | 2024-06-11 | — | — | CN | claimed |
| EP-3750890-B1 | ALKOXYBENZO-FIVE-MEMBERED (SIX-MEMBERED) HETEROCYCLIC AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | SHIJIAZHUANG YILING PHARMACEUTICAL CO LTD (CN) | 2026-04-01 | — | — | EP | disclosed |
| WO-2025007113-A2 | MITOCHONDRIAL COMPLEX I INHIBITORS WITH REDUCED PHOSPHODIESTERASE INHIBITION | OHIO STATE INNOVATION FOUNDATION (US) | 2025-01-02 | — | — | WO | disclosed |
| CN-118165038-A | Cyclic metal ruthenium nitrosyl complex, preparation method and application as NO release photosensitizer | 中南民族大学 | 2024-06-11 | — | — | CN | disclosed |
| US-11396504-B2 | Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof | FUDAN UNIVERSITY (CN) | 2022-07-26 | — | — | US | disclosed |
| US-20210032230-A1 | Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof | SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD (CN) | 2021-02-04 | — | — | US | disclosed |
| US-20210032230-A1 | Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof | SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD (CN) | 2021-02-04 | — | — | US | disclosed |
| EP-3750890-A1 | ALKOXYBENZO-FIVE-MEMBERED (SIX-MEMBERED) HETEROCYCLIC AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Fudan University (CN) | 2020-12-16 | — | — | EP | disclosed |
| EP-3750890-A1 | ALKOXYBENZO-FIVE-MEMBERED (SIX-MEMBERED) HETEROCYCLIC AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Fudan University (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019154047-A1 | ALKOXYBENZO-FIVE-MEMBERED (SIX-MEMBERED) HETEROCYCLIC AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | 复旦大学 | 2019-08-15 | — | — | WO | disclosed |
| WO-2011001089-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-01-06 | — | — | WO | disclosed |
| CN-100491352-C | Asymmetrical cyclic diamine compound | KOWA CO (JP) | 2009-05-27 | — | — | CN | disclosed |
| US-7342116-B2 | Process for producing heterocyclic aldehyde | KOEI CHEMICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| EP-1400513-B1 | UNSYMMETRICAL CYCLIC DIAMINE COMPOUND | KOWA CO (JP) | 2008-01-09 | — | — | EP | disclosed |
| EP-1400513-B1 | UNSYMMETRICAL CYCLIC DIAMINE COMPOUND | KOWA CO (JP) | 2008-01-09 | — | — | EP | disclosed |
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | KOEI CHEMICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
| CN-1520402-A | Unsymmetrical cyclic diamine compound | ������������ʽ���� | 2004-08-11 | — | — | CN | disclosed |
| EP-1400513-A1 | UNSYMMETRICAL CYCLIC DIAMINE COMPOUND | Kowa Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-6552188-B2 | Inhibit cell adhesion and cell infiltration; useful treating asthma, allergies, rheumatic diseases, arteriosclerosis, and inflammation; 2-(3,4,5-trimethoxyphenyl),4-((4-substituted piperazin-1-yl)methyl)pyridine compounds | KOWA CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| US-20030022887-A1 | Unsymmetrical cyclic diamine compound | KOWA CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | ADH1C, ADH1A, AOX1 | ASIC3 3322/4885RECQL 4638/4885LOXL2 173/4885 |
| US-20030022887-A1 | Unsymmetrical cyclic diamine compound | H1-0, DDAH1, AOC1 | ASIC3 446/4885RECQL 1199/4885LOXL2 4426/4885 |
| US-20210032230-A1 | Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof | LIPC, GPR119, VIP | ASIC3 1449/4885RECQL 3691/4885LOXL2 479/4885 |
| US-11396504-B2 | Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof | LIPC, GPR119, VIP | ASIC3 1449/4885RECQL 3691/4885LOXL2 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.